Protein conformational pathology in Alzheimer's and other neurodegenerative diseases; new targets for therapy

Current Alzheimer Research

Volumn 7, Issue 1, 2010, Pages 74-83

  Zerovnik E ^a  

^a JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

AD; Aggresome; Amyloid fibrils; Amyloid toxicity; Autophagy; Channel hypothesis; Chaperones; Metal hypothesis; New therapies; Prefibrillar oligomers; Protein aggregation; Protein conformation

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ALUMINUM; AMYLOID PROTEIN; ASCORBIC ACID; CHOLESTEROL; COPPER; ESTROGEN; IBUPROFEN; IRON; METAL ION; OLIGOMER; PROTEIN; ROSIGLITAZONE; TESTOSTERONE; ZINC;

AGGRESOME; AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOPHAGY; CALCIUM TRANSPORT; CELL INCLUSION; CELL MEMBRANE; CLINICAL TRIAL; COGNITIVE DEFECT; CYTOTOXICITY; DEGENERATIVE DISEASE; DEMENTIA; DIABETES MELLITUS; EUKARYOTE; HUMAN; IN VITRO STUDY; MUTATION; NEUROTRANSMISSION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROKARYOTE; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN MODIFICATION; REVIEW; VACCINATION; VITAMIN SUPPLEMENTATION;

AMYLOID; ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; PROTEIN CONFORMATION; PROTEINS; TAU PROTEINS;

EID: 77949723208     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510790274437     Document Type: Review

References (122)

1. Morishima-Kawashima M, Hara Y. Alzheimer's disease: β-amyloid protein and tau. J Neurosci Res 70: 392-401 (2002).
2. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 26: 207-14 (2003).
3. Weiner HL, Selkoe DJ. Inflamation and therapeutic vaccination in CNS diseases. Nature 420: 879-84 (2002).
4. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307: 1282-88 (2005).
5. Ross CA, Poirier MA. What is the role of protein aggregation in neurodegeneration? Nat Revs 6: 891-898 (2005).
6. Williams AJ, Paulson HL. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci 31: 521-8 (2008).
7. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431: 805-810 (2004).
8. Wang Q, Johnson JL, Agar NYR, Agar JN. Protein Aggregation and Protein Instability Govern Familial Amyotrophic Lateral Sclerosis Patient Survival. PLoS Biol 6: e170 doi:10.1371/journal.pbio.0060170
9. Baumketner A, Krone MG, Shea JE. Role of the familial Dutch mutation E22Q in the folding and aggregation of the 15-28 fragment of the Alzheimer amyloid-β protein. Proc Natl Acad Sci USA 105: 6027-32 (2008).
10. Walsh DM, Selkoe DJ. Aβ Oligomers - a decade of discovery. J Neurochem 101: 1172-84 (2007).
11. Shin J, Lee SY, Kim SH, Kim YB, Cho SJ. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Neuroimage 43:236-44 (2008).
12. Schneider LS. Ginkgo biloba Extract and Preventing Alzheimer Disease. JAMA 300: 2306-08 (2008).
13. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280: 5892-901 (2005).
14. Wilson RS, Mendes De Leon CF, Barnes LL, Schneider JA, Bienias JL, et al. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 287: 742-8 (2002).
15. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80(1): 13-7 (2009).
16. Risner ME, Saunders AM, Altman JFB, Ormandy GC, Craft S, Foley IM, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6: 246-54 (2006).
17. Hirohata M, Ono K, Yamada M. Non-steroidal anti-inflammatory drugs as anti-amyloidogenic compounds. Curr Pharm Des 14(30): 3280-94 (2008).
18. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289: 2651-62 (2003).
19. Driscoll I, Resnick SM. Testosterone and Cognition in Normal Aging and Alzheimer's Disease: an update. Curr Alzheimer's Dis 4: 33-45 (2007).
20. Kagan BL, Hirakura Y, Azimov R, Azimova R, Lin MC. The channel hypothesis of Alzheimer's disease: current status. Peptides 23: 1311-15 (2002).
21. Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443: 774-9 (2005).
22. Kawahara M, Kuroda Y, Arispe N, Rojas E. Alzheimer's amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J Biol Chem 275: 14077-83 (2000).
23. Stefani M, Dobson CM. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 81: 678-99 (2003).
24. Bucciantini M, Rigacci S, Berti A, Pieri L, Cecchi C, Nosi D, et al. Patterns of cell death triggered in two different cell lines by HypFN prefibrillar aggregates. FASEB J 19: 437-9 (2005).
25. Matsuzaki K. Physicochemical interactions of amyloid β-peptide with lipid bilayers. Biochim Biophys Acta 1768: 1935-42 (2007).
26. Tun H, Marlow L, Pinnix I, Kinsey R, Sambamurti K. Lipid rafts play an important role in A beta biogenesis by regulating the secretase pathway. J Mol Neurosci 19: 31-5 (2002).
27. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer amyloid precursor protein depends on lipid rafts. J Cell Biol 160: 113-23 (2003).
28. Kivipelto M, Rovio S, Ngandu T, Kåreholt I, Eskelinen M, Winblad B, et al. Apolipoprotein E epsilon4 Magnifies Lifestyle Risks for Dementia: A Population Based Study. J Cell Mol Med (2008). Mar 4; [Epub ahead of print]
29. Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX. Metals and amyloid-β in Alzheimer's disease : Role of amyloid-β in Alzheimer's disease. Int J Exp Pathol 86: 147-59 (2005).
30. Bush AI, Tanzi RE. Therapeutics for Alzheimer's Disease based on the Metal Hypothesis. Neurotherapeutics 5: 121-32 (2008).
31. Bush AI. Therapeutic targets in the biology of Alzheimer's disease. Curr Opin Psychiatry 14: 341-8 (2001).
32. Crouch PJ, White AR, Bush AI. The modulation of metal bioavailability as a therapeutic strategy for the treatment of Alzheimer's disease. FEBS J 274: 3775-83 (2007).
33. Gaggelli E, Kozlowski H, Valensin D, Valensin G. Copper Homeostasis and Neurodegenerative disorders (Alzheimer's, Prion and Perkinson's Diseases and amyotrophic lateral sclerosis). Chem Rev 106: 1995-2044 (2006).
34. Squier TC. Oxidative stress and protein aggregation during biological aging. Exp Gerontol 36: 1539-1550 (2001).
35. Ding Q, Dimayuga E, Keller JN. Oxidative damage, protein synthesis, and Protein degradation in Alzheimer's disease. Curr Alz Res 4: 73-9 (2007).
36. Petrozzi L, Ricci G, Giglioli NJ, Siciliano G, Mancuso M. Mitochondria in Neurodegeneration. Biosci Rep 27: 87-104 (2007).
37. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-85 (1992).
38. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416: 507-511 (2002).
39. Ceru S, Kokalj SJ, Rabzelj S, Skarabot M, Gutierrez-Aguirre I, Kopitar-Jerala N, et al. Size and morphology of toxic oligomers of amyloidogenic proteins: a case study of human stefin B. Amyloid 15: 147-59 (2008).
40. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al., Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-39 (2002).
41. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8: 79-84 (2005).
42. Wirths O, Multhaup G, Bayer TA. A modified amyloid hypothesis: intraneuronal accumulation of the amyloid peptide - the first step of a fatal cascade. J Neurochem 91: 513-20 (2004). Review.
43. Baglioni S. Prefibrillar Amyloid Aggregates Could Be Generic Toxins in Higher Organisms. J Neurosci 26: 8160-7 (2006).
44. 2+ Increase in Primary Neuronal Cells. J Biol Chem 283: 29950-60 (2008).
45. Goedert M, Spillantini MG, Davies SW. Filamentous nerve cell inclusions in neurodegenerative diseases. Curr Opin Neurobiol 8: 619-32 (1998).
46. Žerovnik E. Amyloid-fibril formation; Proposed mechanisms and relevance to conformational disease. Eur J Biochem 269: 3362-71 (2002).
47. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med 10: S10-S17 (2004).
48. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common pathology. Science 300: 487-89 (2003).
49. Serpell LC, Sunde M, Blake CC. The molecular basis of amyloidosis. Cell Mol Life Sci 53: 871-87 (1997).
50. Anderluh G, Gutierrez-Aguirre I, Rabzelj S, Ceru S, Kopitar-Jerala N, Macek P, et al. Interaction of human stefin B in the prefibrillar oligomeric form with membranes. Correlation with cellular toxicity. FEBS J 272: 3042-51 (2005).
51. Rabzelj S, Viero G, Gutiérrez-Aguirre I, Turk V, Dalla Serra M, Anderluh G, et al. Interaction with model membranes and pore formation by human stefin B - studying the native and prefibrillar states. FEBS J 275: 2455-66 (2008).
52. Guijarro JI, Sunde M, Jones JA, Campbell ID, Dobson CM. Amyloid fibril formation by an SH3 domain. Proc Natl Acad Sci USA 95: 4224-28 (1998).
53. Chiti F, Taddei N, Bucciantini M, White P, Ramponi G, Dobson CM. Mutational analysis of the propensity for amyloid formation by a globular protein. EMBO J 19: 1441-49 (2000).
54. Lopez de la Paz M, Serrano L. Sequence determinants of amyloid fibril formation. Proc Natl Acad Sci USA 101: 87-92 (2004).
55. Pellarin R, Caflish A. Interpreting the Aggregation Kinetics of Amyloid peptides. J Mol Biol 360: 882-892 (2006).
56. Uversky VN, Fink AL. Conformational constraints for amyloid formation: the importance of being unfolded. Biochim Biophys Acta 1698: 131-153 (2004).
57. El Moustaine D, Perrier V, Smeller L, Lange R, Torrent J. Fulllength prion protein aggregates to amyloid fibrils and spherical particles by distinct pathways. FEBS J 275: 2021-31 (2008).
58. Plakoutsi G, Bemporad F, Calamai M, Taddei N, Dobson CM, Chiti F. Evidence for a mechanism of amyloid formation involving molecular reorganization within native-like precursor aggregates. J Mol Biol 351: 910-922 (2005).
59. Nayak A, Sorci M, Krueger S, Belfort G. A universal pathway for amyloid nucleus and precursor formation for insulin. Proteins 74: 556-65 (2009).
60. Serio TR, Cashikar AG, Kowal AS, Sawicki GJ, Moslehi JJ, Serpell L. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 289: 1317-21 (2000).
61. Lee CC, Nayak A, Sethuraman A, Belfort G, McRae GJ. A three-Stage Kinetic Model of Amyloid fibrillation. Biophys J 92: 3448-3458
62. Škerget K, Vilfan A, Pompe-Novak M, Turk V, Waltho JP, Turk D, et al. The mechanism of amyloid-fibril formation by stefin B; temperature and protein concentration dependence of the rates. Proteins 74: 425-436 (2009).
63. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 143: 1883-98 (1998).
64. Kopito RR. Aggresomes, inclusion bodies and protein aggregation, Trends Cell Biol 10: 524-30 (2000).
65. Kopito RR, Sitia R Aggresomes and Russell bodies. Symptoms of cellular indigestion? EMBO Rep 1: 225-231 (2000).
66. Hershko A, Ciechanover A. The ubiquitin system, Annu Rev Biochem 67: 425-79 (1998).
67. Layfield R, Lowe J, Bedford I. The ubiquitin-proteasome system and neurodegenerative disorders. Essays Biochem 41: 157-71 (2005).
68. Cuervo AM. Autophagy: many paths to the same end. Mol Cell Biochem 263: 55-72 (2004).
69. Nedelsky NB, Todd PK, Taylor JP. Autophagy and the ubiquitinproteasome system: Collaborators in neuroprotection. Biochim Biophys Acta 1782: 691-9 (2008).
70. Kaganovich D, Kopito RR, Frydman J. Misfolded proteins partition between two distinct quality control compartments. Nature 454: 1088-95 (2008).
71. Beaudoin S, Goggin K, Bissonnette C, Grenier C, Roucou X. Aggresomes do not represent a general cellular response to protein misfolding in mammalian cells. BMC Cell Biol 9: 59 (2008).
72. Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, Markovic-Plese S, et al. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet 12: 749-57 (2003).
73. Junn E, Lee SS, Suhr UT, Mouradian MM. Parkin accumulation in aggresomes due to proteasome impairment. J Biol Chem 277: 47870-77 (2002).
74. Mittal S, Dubey D, Yamakawa K, Ganesh S. Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Hum Mol Genetics 16: 753-62 (2007).
75. Wigley WC, Fabunmi RP, Lee MG, Marino CR, Muallem S, DeMartino GN, et al. Dynamic association of proteasomal machinery with the centrosome. J Cell Biol 145: 481-90 (1999).
76. Johnston JA, Illing ME, Kopito RR. Cytoplasmic dynein/dynactin mediates the assembly of aggresomes. Cell Motil Cytoskeleton 53: 26-38 (2002).
77. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 279: 4625-31 (2004).
78. Cipollini E, Riccio M, Di Giaimo R, Dal Piaz F, Pulice G, Catania S, et al. Cystatin B and its EPM1 mutants are polymeric and aggregate prone in vivo. Biochim Biophys Acta 1783: 312-22 (2008).
79. Ceru S, Ph D thesis. Mechanism of cytotoxicity of prefibrillar aggregates of stefin B and some chosen mutants in vitro & ex vivo. Medical Faculty, University of Ljubljana (2008).
80. Wilson MR, Yerbury JJ, Poon S. Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mol Biosyst 4: 42-52 (2008).
81. Saibil HR. Chaperone machines in action. Curr Opin Struct Biol 18: 35-42 (2008).
82. Meriin AB, Sherman MY. Role of Molecular chaperones in neurodegenerative disorders. Int J Hyperthermia 21: 403-19 (2005).
83. Meehan S, Knowles TP, Baldwin AJ, Smith JF, Squires AM, Clements P, et al. Characterisation of Amyloid Fibril Formation by Small Heat-shock Chaperone Proteins Human αA-, αB- and R120G αB-Crystallins. J Mol Biol 372: 470-84 (2007).
84. Rekas A, Adda CG, Andrew Aquilina J, Barnham KJ, Sunde M, Galatis D, et al. Interaction of the Molecular Chaperone αB-Crystallin with α-Synuclein: Effects on Amyloid Fibril Formation and Chaperone Activity. J Mol Biol 340: 1167-83 (2004).
85. Raman B, Ban T, Sakai M, Pasta SY, Ramakrishna T, Naiki H, et al. Alpha B-crystallin, a small heat-shock protein, prevents the amyloid fibril growth of an amyloid peptide and beta2-microglobulin. Biochem J 392: 573-81 (2005).
86. Reddy GB, Kumar PA, Kumar MS. Chaperone-like activity and hydrophobicity of α-crystallin. IUBMB Life 58: 632-41 (2006).
87. Rekas A, Jankova L, Thorn DC, Cappai R, Carver JA. Monitoring the prevention of amyloid fibril formation by alpha-crystallin. Temperature dependence and the nature of the aggregating species. FEBS J 274: 6290-304 (2007).
88. Stege GJ, Renkawek K, Overkamp PS, Verschuure P, van Rijk AF, Reijnen-Aalbers A, et al. The molecular chaperone alphaB-crystallin enhances amyloid beta neurotoxicity. Biochem Biophys Res Commun 262: 152-56 (1999).
89. Douglas PM, Treusch S, Ren HY, Halfmann R, Duennwald ML, Lindquist S, et al. Chaperone-dependent amyloid assembly protects cells from prion toxicity. Proc Natl Acad Sci USA 105: 7206-11 (2008).
90. Wilhelmus MMM, de Wall RMW, Verneek MM. Heat shock proteins and amateur chaperones in amyloid-beta accumulation and clearance in Alzheimer's disease. Mol Neurobiol 35: 203-16 (2007).
91. Ravikumar B, Rubinsztein DC. Role of autophagy in the clearance of mutant huntingtin: a step towards therapy? Mol Aspects Med 27: 520-27 (2006).
92. Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol 3: 331-8 (2007).
93. Shacka JJ, Roth KA, Zhang J. The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy. Front Biosci 13: 718-36 (2008).
94. Turk V, Turk B, Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J 20: 4629-33 (2001).
95. Turk V, Stoka V, Turk D. Cystatins: Biochemical and structural properties, and medical relevance. Front Biosci 13: 5406-5420 (2008).
96. Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, et al. Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging 25: 1033-1043 (2004).
97. Levy E. Cystatin C: a potential target for Alzheimer's treatment, Expert Rev. Neurotherapeutics 8: 687-689 (2008).
98. Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, Klein AM, et al. Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat Genet 39: 1440-1442 (2007).
99. Kopitar-Jerala N. The role of cystatins in cells of the immune system. FEBS Lett 580: 6295-6301 (2006).
100. Wisniewski T, Sigurdsson EM Therapeutic approaches for prion and Alzheimer's diseases. FEBS J 274: 3784-98 (2007).
101. Barten DM, Albright CF. Therapeutic strategies for Alzheimer's disease. Mol Neurobiol 37: 171-86 (2008).
102. Lazo ND, Maji SK, Fradinger EA, Bitan G, Teplow DB. The Amyloid beta protein, in Amyloid Proteins; the beta sheet conformation and disease, Sipe JD (Ed) Wiley-VCH: Weinheim pp. 285-492 (2005).
103. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castaño EM, Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 4: 822-6 (1998).
104. Tampellini D, Magrané J, Takahashi RH, Li F, Lin MT, Almeida CG, et al. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem 282: 18895-906 (2007).
105. Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, et al. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci 24: 991-8 (2004).
106. Farris W, Schütz SG, Cirrito JR, Shankar GM, Sun X, George A, et al. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol 171: 241-51 (2007).
107. Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 15: 433-42 (2006).
108. Yang J, Bridges K, Chen KY, Liu AY. Riluzole increases the amount of latent HSF1 for an amplified heat shock response and cytoprotection. PLoS ONE 3: e2864 (2008).
109. Eubanks LM, Rogers CJ, Beuscher IV AE, Koob GF, Olson AJ, Dickerson TJ, et al. A Molecular Link between the Active Component of Marijuana and Alzheimer's Disease Pathology. Mol Pharmaceutics 3: 773-7 (2006).
110. Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, Mueller-Steiner S, et al. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimers disease. Neuron 60: 247-57 (2008).
111. Yang DS, Kumar A, Stavrides P, Peterson J, Peterhoff CM, Pawlik M, et al. Cystatin B deletion in a mouse model of Alzheimers disease, TgCRND8, ameliorates both autophagic-lysosomal and amyloid pathologies. Alzheimers Dementia 4, T223 (2008).
112. Krebs MR, Wilkins DK, Chung EW, Pitkeathly MC, Chamberlain AK, Zurdo J, et al. Formation and seeding of amyloid fibrils from wild-type hen lysozyme and a peptide fragment from the beta-domain. J Mol Biol 300: 541-9 (2000).
113. Goers J, Permyakov SE, Permyakov EA, Uversky VN, Fink AL. Conformational prerequisites for alpha-lactalbumin fibrillation. Biochemistry 41: 12546-51 (2002).
114. Hamada D, Dobson CM. A kinetic study of beta-lactoglobulin amyloid fibril formation promoted by urea. Protein Sci 11: 2417-26 (2002).
115. Chiti F, Webster P, Taddei N, Clark A, Stefani M, Ramponi G, et al. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci USA 96: 3590-4 (1999).
116. Taddei N, Capanni C, Chiti F, Stefani M, Dobson CM, Ramponi G. Folding and aggregation are selectively influenced by the conformational preferences of the alpha-helices of muscle acylphosphatase. J Biol Chem 276: 37149-54 (2001).
117. Žerovnik E, Pompe-Novak M, Škarabot M, Ravnikar M, Musevic I, Turk V. Human stefin B readily forms amyloid fibrils in vitro. Biochim Biophys Acta 1594: 1-5 (2002).
118. Damaschun G, Damaschun H, Fabian H, Gast K, Kröber R, Wieske M, et al. Conversion of yeast phosphoglycerate kinase into amyloid-like structure. Proteins 39: 204-11 (2000).
119. Chiti F, Bucciantini M, Capanni C, Taddei N, Dobson CM, Stefani M. Solution conditions can promote formation of either amyloid protofilaments or mature fibrils from the HypF N-terminal domain. Protein Sci 10: 2541-7 (2001).
120. Konno T, Murata K, Nagayama K. Amyloid-like aggregates of a plant protein: a case of a sweet-tasting protein, monellin. FEBS Lett 454: 122-6 (1999).
121. Johansson J. Membrane properties and amyloid fibril formation of lung surfactant protein C. Biochem Soc Trans 29: 601-6 (2001).
122. Souillac PO, Uversky VN, Millett IS, Khurana R, Doniach S, Fink AL. Elucidation of the molecular mechanism during the early events in immunoglobulin light chain amyloid fibrillation. Evidence for an off-pathway oligomer at acidic pH. J Biol Chem 277: 12666-79 (2002).